biomed devic servic
durabl secular trend appear stay
deliv strong revenu beat us beat ep
beat us affirm thesi durabl global secular trend next-
gener sequenc appear stay time year quarter
stock appear flattish after-hour like sinc rais revenu
guid despit beat like pull forward order china
declin comment guidanc next year fine us
expect continu track news flow sequenc project scale globe
continu consid top pick must stock on-going
strength popul sequenc project direct-to-consum genet test liquid
biopsi studi keep us posit reiter buy rate pt
result rev y/i beat y/i /street
larg driven beat array instrument beat sequenc
instrument sequenc consum grew y/i slightli
adj ep toppl adj gm
y/i beat adj om y/i beat
rais bottom line guid reiter top-lin rais adj ep guid
y/i y/i reiter
revenue guid y/i growth rais top line attribut
revenu previous contempl china got pull
expect rev flat slightli despit
pull-forward demand china though sens conserv guid
guid adj ep vs prior
novaseq drove rev sequenc instrument
q/q driven continu strong adopt novaseq primarili
reiter guid place novaseq unit
tariff tariff neglig howev indic tariff
appli instrument indic present pay
tariff consum though awar one compani adjac
subject tariff bear watch
model nudg revenu estim y/i
y/i revenu y/i y/i
adj ep y/i maintain revenue
growth rais adj ep y/i rais
revenu estim y/i rais adj
ep y/i
exom patient respons question ceo franci desouza indic
convers health systems/idn exom
sequenc patient clinic set indic partnership
geising spur convers larg system integr deliveri
network believ greater adopt systemat would add major upsid
sequenc consum growth think take time play
price close busi octob
domin global leader next
gener sequenc instrument
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
array servic total services/oth rev y/i light
microarray consum y/i beat
microarray instrument revenu drove strong beat come well
well last quarter driven like stock ahead
busi expect holiday season microarray servic rev declin y/i
line manag commentari normal season trend expect
microarray revenu slightli due declin microarray instrument
off-set increas microarray consum growth believ
commentari conserv manag indic us forecast
inform largest custom commun
call number specif popseq project call
written recent note
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
biomed devic servic
biomed devic servic
biomed devic servic
biomed devic servic
